文献速递焦虑、强迫与应激相关障碍

选择性5-羟色胺再摄取抑制剂治疗成人强迫症的个体患者数据荟萃分析

Individual patient data meta-analysis of placebo-controlled trials of selective serotonin reuptake inhibitors submitted for regulatory approval in adult obsessive-compulsive disorder.
PubMed 文献 · Br J Psychiatry · 2025-05-15

该个体患者数据荟萃分析纳入11项提交荷兰监管机构的短期随机安慰剂对照试验(n=2372),评估SSRIs治疗成人强迫症的疗效与可接受性。结果显示SSRIs在YBOCS评分改善上优于安慰剂(均差2.65分,95%CI 1.85-3.46,p<0.0001),效应量小(Hedges' g=0.33),应答比值比为2.21,需治疗人数为7,可接受性与安慰剂相当,且疗效不受基线患者特征影响。

要点

  • SSRIs治疗成人强迫症优于安慰剂,但效应量小(Hedges' g=0.33)。
  • 应答比值比2.21,需治疗人数为7,可接受性与安慰剂相当。
  • 年龄、性别、病情严重度等基线特征未修饰疗效。

核心结论

  • SSRIs治疗成人强迫症可接受性好且优于安慰剂,但效应中等且独立于基线患者特征。

研究设计与样本

  • 个体患者数据荟萃分析,纳入11项提交荷兰监管机构的行业资助短期随机安慰剂对照SSRIs试验(n=2372),采用两阶段荟萃分析。

主要发现

  • SSRIs相对安慰剂的YBOCS评分均差为2.65分(95%CI 1.85-3.46,p<0.0001),效应量小(Hedges' g=0.33)。
  • 应答比值比为2.21(95%CI 1.72-2.83,p<0.0001),需治疗人数为7。
  • SSRIs与安慰剂的可接受性相当。
  • 年龄、性别、病情严重度、抑郁症状、体重、病程及抗抑郁药使用史未修饰症状变化或应答。

关键数值与推荐

  • 主要结局为YBOCS评分变化在活性治疗与安慰剂间的差异。
  • 应答定义为YBOCS评分降低≥35%的比值比。
  • 可接受性定义为全因停药的比值比。

临床怎么用

  • SSRIs可作为成人强迫症的有效药物治疗选择,但需预期效应量较小。
  • 基线患者特征不影响疗效,暗示无需据此选择是否使用SSRIs。

局限性

  • 仅纳入提交荷兰监管机构的行业资助短期试验,试验持续时间10至13周。
  • 排除3项因数据缺失的试验,可能影响代表性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are the preferred pharmacological treatment for obsessive-compulsive disorder (OCD). However, insufficient response is common and it remains unclear whether specific patient-level factors influence the likelihood of treatment response. AIMS: To determine the efficacy and acceptability of SSRIs in adult OCD, and to identify patient-level modifiers of efficacy. METHODS: We conducted an individual patient data meta-analysis (IPDMA) of industry-sponsored short-term, randomised, placebo-controlled SSRI trials submitted for approval to the Dutch regulatory agency to obtain marketing approval for treating OCD in adults. We performed a two-stage meta-analysis, using crude data of available trials. The primary outcome was the difference in Yale-Brown Obsessive-Compulsive Scale (YBOCS) change between active treatment and placebo. Secondary outcomes were differences in response (defined as the odds ratio of ≥35% YBOCS point reduction) and acceptability (defined as the odds ratio for all-cause discontinuation). We examined the modifying effect of baseline characteristics: age, gender, illness severity, depressive symptoms, weight, illness duration and history of antidepressant use. RESULTS: After excluding three trials because of missing data, we analysed results from 11 trials (79% of all submitted trials, n = 2372). The trial duration ranged from 10 to 13 weeks. Mean difference of SSRIs relative to placebo was 2.65 YBOCS points (95% CI 1.85-3.46, p < 0.0001), equalling a small effect size (0.33 Hedges' g). The odds ratio for response was 2.21 in favour of active treatment (95% CI 1.72-2.83, p < 0.0001), with a number needed to treat of seven. Patient characteristics did not modify symptom change or response. Acceptability was comparable for SSRIs and placebo. CONCLUSIONS: Our IPDMA showed that SSRIs are well accepted and superior to placebo for treating OCD. The effects are modest and independent of baseline patient characteristics.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Cohen SE, Storosum BW, Zantvoord JB, et al. Individual patient data meta-analysis of placebo-controlled trials of selective serotonin reuptake inhibitors submitted for regulatory approval in adult obsessive-compulsive disorder. Br J Psychiatry. 2025. PMID: 40369939. doi:10.1192/bjp.2025.87

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。